Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence D True

Showing results (131-140 of 204) with videos related to

Pageof 21
Sort By:
Plos One|September 9, 2014
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesRyan R Gordon, Mengchu Wu, Chung-Ying Huang, et al.
Archives of Pathology & Laboratory Medicine|October 9, 2018
Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate CancerLiana B Guedes, Carlos L Morais, Helen Fedor, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 26, 2013
Prostate cancer cell phenotypes based on AGR2 and CD10 expressionMelissa E Ho, Sue-Ing Quek, Lawrence D True, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2019
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate CancerAlexandra N Corella, Ma Victoria Andrea Cabiliza Ordonio, Ilsa Coleman, et al.
The Prostate|March 19, 2016
Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancerMartine P Roudier, Brian R Winters, Ilsa Coleman, et al.
Cancer Discovery|August 15, 2014
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasisJared M Lucas, Cynthia Heinlein, Tom Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2015
SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate CancerXiaotun Zhang, Ilsa M Coleman, Lisha G Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate CancerDiana C DeLucia, Thomas M Cardillo, Lisa Ang, et al.
Oncotarget|February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancerDebashis Sahoo, Wei Wei, Heidi Auman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptorsEddy J Chen, Adam G Sowalsky, Shuai Gao, et al.
Pageof 21

Showing results (131-140 of 204) with videos related to

Sort By:
Pageof 21
Plos One|September 9, 2014
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesRyan R Gordon, Mengchu Wu, Chung-Ying Huang, et al.
Archives of Pathology & Laboratory Medicine|October 9, 2018
Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate CancerLiana B Guedes, Carlos L Morais, Helen Fedor, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 26, 2013
Prostate cancer cell phenotypes based on AGR2 and CD10 expressionMelissa E Ho, Sue-Ing Quek, Lawrence D True, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2019
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate CancerAlexandra N Corella, Ma Victoria Andrea Cabiliza Ordonio, Ilsa Coleman, et al.
The Prostate|March 19, 2016
Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancerMartine P Roudier, Brian R Winters, Ilsa Coleman, et al.
Cancer Discovery|August 15, 2014
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasisJared M Lucas, Cynthia Heinlein, Tom Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2015
SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate CancerXiaotun Zhang, Ilsa M Coleman, Lisha G Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate CancerDiana C DeLucia, Thomas M Cardillo, Lisa Ang, et al.
Oncotarget|February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancerDebashis Sahoo, Wei Wei, Heidi Auman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptorsEddy J Chen, Adam G Sowalsky, Shuai Gao, et al.
Pageof 21